Divi’s Laboratories Ltd., a leading pharmaceutical company, announced a 49.3% decline in consolidated net profit for the April-June quarter, with net profit at Rs 356 crore compared to Rs 702 crore last year.
Revenue from operations, however, increased by 21.2% to Rs 1778 crore from Rs 2255 crore in the previous fiscal. Sequentially, net profit improved by 10.9% from Rs 321 crore in the Jan-Mar quarter of FY23.
Divi’s Laboratories also saw a shift in operational performance, with EBITDA falling 40.6% to Rs 504 crore from Rs 847 crore in the base quarter. The EBITDA margin, or operating profit margin, dropped by 930 basis points to 28.3% in the reported quarter compared to 37.6% in the same quarter last year.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.